Calcium channel blockers: Pharmacology and place in therapy of pediatric hypertension

Pediatric Nephrology

Volumn 15, Issue 3-4, 2000, Pages 302-316

  Flynn, Joseph T ^a   Pasko, Deborah A ^a  

^a Pediatric Nephrology   (United States)

Author keywords

Calcium channel blockers; Children; Hypertension; Pharmacokinetics

Indexed keywords

AMLODIPINE; ANTICONVULSIVE AGENT; CADMIUM; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN A; CYTOCHROME P450 INHIBITOR; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; ENZYME INDUCING AGENT; FELODIPINE; ISRADIPINE; MIBEFRADIL; NICARDIPINE; NIFEDIPINE; OMEGA AGATOXIN; OMEGA CONOTOXIN GVIA; PYRROLE DERIVATIVE; VERAPAMIL;

ADOLESCENT; ANTIHYPERTENSIVE THERAPY; AREA UNDER THE CURVE; CHILD; CHILDHOOD DISEASE; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSAGE FORM; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; FLUSHING; FOOD DRUG INTERACTION; GINGIVA HYPERPLASIA; HEADACHE; HUMAN; HYPERTENSION; INFANT; LEG EDEMA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TACHYCARDIA;

CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS; CHILD; HUMANS; HYPERTENSION;

EID: 0033638940     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004670000480     Document Type: Review

References (148)

1. Treatment of hypertension in children
2. Hypertension in pediatric patients
3. Update on the 1987 Task Force Report on High Blood Pressure in Children and Adolescents: A working group report from the National High Blood Pressure Education Program
4. Calcium antagonism in vascular smooth muscle cells
5. Molecular biology of calcium channels in the cardiovascular system
6. Interactions between membrane potential and intracellular calcium concentration in vascular smooth muscle
7. Mechanisms of action of calcium channel antagonists
8. Classification of calcium channels and the sites of action of drugs modifying channel function
9. The molecular structure and gating of calcium channels
10. Molecular biology of calcium channels
11. 2+ channel function and drug action
12. Molecular basis of the diversity of calcium channels in cardiovascular tissues
13. The physiological and pharmacological significance of cardiovascular T-type, voltage-gated calcium channels
14. Pharmacology of calcium channels in cardiac muscle, vascular muscle and neurons
15. Calcium channel blockers in myocardial and cerebral ischemia: A clinician's review from bench to bedside
16. 2+ channels distributed in cardiovascular system
17. Molecular determinants of drug binding and action on L-type calcium channels
18. Dihydropyridine binding of the calcium channel complex from skeletal muscle is modulated by subunit interaction
19. Regulation of L-type calcium channels of vascular smooth muscle cells
20. Calcium function in vascular smooth muscle
21. The cellular ionic basis of hypertension and allied clinical conditions
22. The classification of calcium antagonists and their selection in the treatment of hypertension. A reappraisal
23. Classification of calcium antagonists
24. Classification and tissue selectivity of calcium antagonists
25. Third generation calcium entry blockers
26. The pharmacokinetic profile of amlodipine
27. Amlodipine: A new calcium antagonist
28. The pharmacological properties of lipophilic calcium antagonists
29. The clinical consequences of the absorption, distribution, metabolism, and excretion of amlodipine
30. Pharmacokinetics of calcium antagonists under development
31. The safety and efficacy of the calcium channel blocker (CCB) amlodipine in the treatment of secondary hypertension in children
32. Amlodipine effectively controls blood pressure in children with hypertension
33. Efficacy of amlodipine in pediatric bone marrow transplant patients
34. Amlodipine once-daily in systemic hypertension
35. Efficacy of amlodipine in pediatric patients with hypertension
36. The pharmacokinetics and pharmacology of oral diltiazem in normal volunteers
37. Clinical pharmacokinetics of vasodilators: Part I
38. Pharmacokinetics of diltiazem in patients with unstable angina pectoris
39. Serum binding of diltiazem in humans
40. Effects of intravenous diltiazem administration in patients with inducible tachycardia
41. Felodipine kinetics in healthy men
42. Clinical pharmacokinetics of felodipine: A summary
43. Felodipine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension
44. The pharmacokinetics of extended release felodipine in children
45. An acute dose-response pharmacodynamic evaluation of orally administered isradipine (PN-200-110) in hypertensive patients
46. Cardiovascular and renal effects of single administration of three different doses of isradipine in hypertensive patients: Dose-response curves of the different effects
47. Isradipine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease
48. Isradipine therapy in hypertensive pediatric patients
49. Efficacy of isradipine as an antihypertensive agent in children
50. Immediate and longer-term effects of nicardipine at rest and during exercise, in patients with coronary artery disease
51. Non-invasive measurement of the haemodynamic effects of nicardipine in normotensive subjects
52. Plasma protein binding and erythrocyte partitioning of nicardipine in vitro
53. Nifedipine: Kinetics and dynamics in healthy subjects
54. Nifedipine kinetics and bioavailability after single intravenous and oral doses in normal subjects
55. A crossover comparison of extended release felodipine with prolonged action nifedipine in hypertension
56. Use of calcium-channel blockers in pediatric renal transplant recipients
57. Nifedipine: Influence of renal function and pharmacokinetic/hemodynamic relationship
58. Bioequivalence of verapamil hydrochloride extended-release pellet-filled capsules when opened and sprinkled on food and when swallowed intact
59. Prolongation of verapamil elimination kinetics during chronic oral administration
60. Verapamil and norverapamil plasma levels in infants and children during chronic treatment
61. Short and long-term effects of calcium entry blockers on the kidney
62. Repetitive natriuresis and blood pressure. Long-term calcium entry blockade with isradipine
63. The diuretic effect of calcium entry blockade in normals and hypertensive patients
64. Effects of different calcium antagonists on proteinuria associated with diabetes mellitus
65. Therapeutic efficacy of different antihypertensive drugs in diabetic nephropathy: An updated meta-analysis
66. Antihypertensive treatment of patients with proteinuric renal diseases: Risks or benefits of calcium channel blockers?
67. Comparison between the effects of amlodipine and lisinopril on proteinuria in nondiabetic renal failure: A double-blind, randomized prospective study
68. Class differences in the effects of calcium channel blockers in the rat remnant kidney model
69. Antiproteinuric effect of verapamil in children with glomerulonephritis
70. Renal functional reserve in calcium channel blocker-treated hypertensive recipients of kidney transplant
71. The beneficial effects of oral nifedipine on cyclosporine-treated renal transplant recipients - A randomised prospective study
72. Effect of nifedipine on renal allograft function and survival beyond one year
73. Effect of nitrendipine on renal function in renal-transplant patients treated with cyclosporin: A randomised trial
74. Withdrawal of Posicor from market [Cardiovascular news]
75. Amlodipine increases cyclosporine levels in hypertensive renal transplant patients: Results of a prospective study
76. Antihypertensive effect of amlodipine and lack of interference with cyclosporine metabolism in renal transplant recipients
77. Safety, tolerability, and pharmacokinetic actions of diltiazem in pediatric liver transplant recipients on cyclosporine
78. Pharmacokinetic interactions between microemulsion formulated cyclosporine A and diltiazem in renal transplant recipients
79. Diltiazem increases tacrolimus concentrations
80. Calcium antagonists: Drug interactions of clinical significance
81. The interaction of the calcium channel blockers verapamil and nifedipine with cyclosporin A in pediatric renal transplant patients
82. The effects of calcium channel blockers on cyclosporine and its metabolites in renal transplant recipients
83. Effect of calcium-channel blockers on cyclosporine clearance and use in renal transplant patients
84. Drug interactions: Part I
85. Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers
86. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression
87. A comparative review of the adverse effects of calcium antagonists
88. Felodipine-induced gingival hyperplasia
89. Medically induced gingival hyperplasia
90. Regression of nifedipine-induced gingival hyperplasia following switch to a same class calcium channel blocker, isradipine
91. Hemodynamic effects of calcium antagonists in hypertension
92. Hemodynamic effects of verapamil in children and adolescents with hypertrophic cardiomyopathy
93. Verapamil therapy in infants with hypertrophic cardiomyopathy
94. Verapamil: An effective calcium channel blocking agent for pediatric patients
95. Verapamil/beta-blocker interaction: A review
96. Profile of paediatric patients with pulmonary hypertension judged by responsiveness to vasodilators
97. Diltiazem reduces pulmonary arterial pressures in recurrent pulmonary hypertension associated with pulmonary hypoplasia
98. Effect of chronic treatment with the calcium antagonist diltiazem in Duchenne muscular dystrophy
99. Regression of calcinosis during diltiazem treatment in juvenile dermatomyositis
100. Negligible sublingual absorption of nifedipine
101. Nifedipine in hypertensive emergencies in children
102. Nifedipine in hypertensive crises of infants and children
103. Effect of sublingual or oral nifedipine in the treatment of hypertension
104. Sublingual nifedipine in acute severe hypertension
105. Calcium blocking agents in pediatric emergency care
106. Stability of isradipine in an extemporaneously compounded oral liquid
107. Persistence of anti-hypertensive effect after 'missed doses' of calcium antagonist with long (amlodipine) vs. short [diltiazem] elimination half-life
108. Stability of amlodipine besylate in two liquid dosage forms
109. Intravenous verapamil in the treatment of paroxysmal supraventricular tachycardia in children
110. Effect of intravenous infusion of verapamil in patients of severe hypertension
111. Treatment of hypertensive crisis
112. Management of hypertensive emergencies
113. Intravenous nicardipine for the treatment of severe hypertension
114. A comparison of intravenous nicardipine and sodium nitroprusside in the immediate treatment of severe hypertension
115. Intravenous nicardipine in hypertensive children
116. Intravenous nicardipine in hypertensive preterm infants
117. Nicardipine for hypertensive emergencies in children with renal disease
118. Safety and efficacy of nicardipine for hypertensive emergencies in children
119. Nifedipine: Dose-related increase in mortality in patients with coronary heart disease
120. The risk of myocardial infarction associated with antihypertensive drug therapies
121. Final outcome results of the multicenter isradipine diuretic atherosclerosis study (MIDAS)
122. 'Inappropriate' physician habits in prescribing oral nifedipine capsules in hospitalized patients
123. Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies?
124. Effects of calcium antagonists on the risks of coronary heart disease, cancer and bleeding
125. The safety of calcium-channel blockers
126. Effect of long-acting and short-acting calcium antagonists on cardiovascular outcomes in hypertensive patients
127. Safety of long-acting dihydropyridine calcium channel blockers in hypertensive patients
128. Symptomatic hypotension induced by nifedipine in the acute treatment of severe hypertension
129. Oral nifedipine in the treatment of hypertensive urgency: Cerebrovascular accident following a single dose
130. The use of sublingual nifedipine. A continuing concern
131. Short-acting nifedipine
132. Nifedipine-induced transient cerebral ischemia in a child with Cockayne syndrome
133. A moratorium should be placed on the use of short-acting nifedipine for hypertensive crises
134. Adverse neurologic events associated with nifedipine use in childhood hypertension
135. Special considerations in pediatric liver transplantation
136. Evaluation of five procedures for measuring nonstandard doses of nifedipine liquid
137. Intravenous labetalol in the treatment of severe hypertension and hypertensive emergencies
138. Minoxidil for control of acute blood pressure elevation in chronically hypertensive children
139. Verapamil blocks basal and angiotensin II-induced RNA synthesis of rat aortic vascular smooth muscle
140. Effect of calcium antagonists on sympathetic activity
141. Trials of antihypertensive therapies in children